Senseonics Holdings, Inc., was originally incorporated in Nevada on June 26, 2014. On December 4, 2015, the company was re-incorporated in Delaware. The company is a medical technology company focused on developing and manufacturing blood glucose monitoring products designed to change the lives of the global diabetes community with differentiated, long-term implantable blood glucose management technology. The company's implantable CGMs, including the Eversense E3 continuous blood glucose monitoring system version, are designed to continuously and accurately measure blood glucose levels in diabetic patients through subcutaneous sensors, detachable and rechargeable smart transmitters, and convenient applications for real-time diabetes monitoring and management for up to six months, compared to seven to 14 days for non-implantable CGM systems. 

Expected P&L on Expiry

Key Stats

Pricing Model

About SENS20270115C7.5